Articles & Analysis
Week of 2026-W08
Business Post Weekly Intelligence Briefing
Irish Business News & Official Records — Week of 19–25 February 2026
Source: ARTICLES | Period: 2026-02-19 to 2026-02-25
Stripe at $159bn, Revolut eyeing $100bn, and Irish pharma in the crosshairs: a week when Ireland's tech and trade exposure came into sharp focus
Over the past seven days, 211 articles published by the Business Post mapped a week of extraordinary contrasts for Irish business: the Collison brothers' Revolut and Stripe reached valuations that would make them two of the most valuable companies ever founded in Ireland, while the US Supreme Court's tariff ruling put the pharmaceutical sector — the backbone of Irish exports — squarely in Donald Trump's sights. Meanwhile, a €1.7 billion data centre financing deal, a €1.5 million talent agency dividend, and a logistics firm's High Court battle with its landlord rounded out a week that was anything but quiet.
The dominant theme was Ireland's exposure to global macro forces: US tariff policy, AI investment cycles, and European trade architecture all intersected with Irish corporate interests in ways that will shape the next 12 months. Vish Gain led coverage with 57 articles, Emma Hanrahan contributed 53, and Oisín Gaffey drove the Irish corporate beat with 13.
By the Numbers
| Metric | Value | Signal |
|---|---|---|
| Stripe total payments processed (2025) | $1.9 trillion | Up 34% YoY |
| Revolut current valuation | $75 billion | Target $100bn+ in H2 2026 |
| Diageo net sales change | -4% | Dividend cut 51% |
| Flutter share price decline (2026 YTD) | -47% | BofA offloads €2.5bn stake |
| Irish commercial RE investment 2025 | €2.4 billion | Flat YoY; +30% forecast 2026 |
| Echelon Data Centres financing | €1.7 billion | Morgan Stanley landmark deal |
| Interpath Ireland revenue growth | +50% to €19.6m | Losses cut from €5.7m to €1m |
| Irish avg weekly earnings Q4 2025 | +3.1% YoY | Hourly up 3.4% |
Irish Tech Ascendancy Meets Global Trade Turbulence
This week's Business Post coverage broke into two distinct narratives: the extraordinary rise of Irish-founded fintech and digital infrastructure companies, and the mounting pressure on Ireland's pharmaceutical and aviation sectors from US trade policy. The Collison brothers' Stripe and the UK-based but Ireland-rooted Revolut both made headlines for valuations that would have seemed fantastical a decade ago — while the Supreme Court's tariff ruling triggered immediate warnings about Ireland's pharma exposure. These are not separate stories: they are two sides of Ireland's position as a high-value node in the global digital and pharmaceutical economy.
Top Stories This Week — Ranked by Business Impact
| Story | Entity | Key Figure | Signal |
|---|---|---|---|
| Stripe hits $159bn valuation | Stripe / Collison Bros | $1.9trn payments processed | Landmark |
| Stripe explores PayPal acquisition | Stripe / PayPal | Early-stage talks | Watch |
| Revolut eyes $100bn share sale | Revolut Ltd | 3m Irish customers, 200 staff | Pre-IPO |
| Echelon secures €1.7bn financing | Echelon Data Centres | 1.2 GW European capacity | Landmark |
| Irish pharma in US crosshairs | Irish pharma sector | Pharma exempt from 10% tariff — for now | Risk |
| BofA offloads €2.5bn Flutter stake | Flutter Entertainment | Stock -47% in 2026 | Distress |
| Diageo dividend cut 51% | Diageo | Net sales -4%, new CEO restructuring | Restructure |
| EU airport slot ruling threatens Dublin | Dublin Airport / US airlines | CJEU advocate general opinion | Risk |
| Uniphar €200m EBITDA target | Uniphar | 330,000 sq ft Dublin distribution centre | Growth |
| Interpath Ireland 50% revenue growth | Interpath Ireland | Revenue €19.6m; parent sold for £800m | Standout |
Sector Breakdown — Coverage by Theme
Financial Performance — Key Companies in the News
| Company | Key Metric | Value | Context |
|---|---|---|---|
| Stripe | Payments processed 2025 | $1.9 trillion | +34% YoY; Dublin subsidiary revenue $5.1bn |
| Revolut | Revenue 2025 (forecast) | £4.1 billion | 3m Irish customers; $75bn current valuation |
| Uniphar | EBITDA target 2028 | €200 million | Pharma division highest-margin growth driver |
| Interpath Ireland | Revenue 2025 | €19.6 million | +50% YoY; losses cut from €5.7m to €1m |
| Diageo | Net sales change H1 2026 | -4% | Dividend cut from 103.5c to min 50c per share |
| Flutter Entertainment | Share price YTD 2026 | -47% | BofA offloads €2.5bn stake |
| Noel Kelly Management (Holdings) | Dividends received 2025 | €1.5 million | €1m from NK Management + €550k from CMS |
| Echelon Data Centres | Financing secured | €1.7 billion | Morgan Stanley; 1.2 GW European capacity |
What the Official Records Reveal
Business Post coverage this week told compelling stories — but the official records add layers the articles alone cannot. When BP reports a €1.5 million dividend from a talent agency holding company, the CRO filing reveals a deliberate corporate architecture built in 2019. When BP reports Revolut eyeing a $100 billion valuation, the CRO shows two separate Irish-registered entities at Dublin Landings — a bank and a payments company — quietly embedding the neobank into the Irish regulatory fabric. And when BP reports a logistics firm's High Court battle, the judgments index reveals this is not the first time Primeline has been in court over commercial disputes. The connections are the story.
Business Post reported this week that Revolut Ltd is eyeing a fresh share sale at a $100 billion valuation, with 3 million Irish customers and around 200 employees in Ireland. CRO records confirm two separate Irish-registered entities: Revolut Ltd (company 909724, registered January 2022) and Revolut Bank UAB (company 909790, registered May 2022), both at 2 Dublin Landings, North Wall Quay, Dublin 1. The dual-entity structure — a payments company and a bank — reflects Revolut's regulatory strategy of separating its banking licence from its broader payments operations. Meanwhile, Stripe's Dublin subsidiary reported $5.1 billion in turnover in 2024, a $1.3 billion jump year-on-year. Two Irish-founded or Irish-rooted companies now represent a combined notional value approaching $260 billion — more than the entire Irish stock exchange. The question for 2026: which of them files for a public listing first, and where?
According to Business Post, Noel Kelly Management (Holdings) Limited received €1.5 million in dividends in 2025 — €1 million from Cleary Consultancy (NK Management) and €550,000 from Century Merchandising Services (CMS). CRO records show the holding company was incorporated on 6 June 2019 at Unit B2, Calmount Office Park, Ballymount, Dublin 12 (eircode D12YR44), with Noel Kelly (DOB 24/11/1962) as sole director and Catriona Cleary Kelly as secretary. The issued share capital stands at just €738 — a nominal figure for a company that channels over €1.5 million annually. The 2019 incorporation date is significant: it suggests the holding structure was established deliberately, likely for tax efficiency and succession planning. The article notes Kelly had put €372,000 into the company which was repaid during the year — a director's loan repayment that further clarifies the cash flow mechanics. CMS profits rose from €339,000 to €428,000 in 2025, suggesting the marketing agency is growing alongside the talent roster. The 2025 accounts will be the real test of whether the dividend pace is sustainable.
Business Post reported that Irish logistics firm Primeline's multi-million landlord row has reached the High Court, with the company claiming €6.7 million in lost revenue due to construction delays at its Cloverhill Industrial Estate warehouses. Primeline is suing Green Urban Logistics Airways for breach of contract, nuisance, and negligent misrepresentation; the landlord has countersued for €1.42 million in unpaid rent. The judgments index reveals this is not Primeline's first High Court appearance: Primeline VNE Limited appeared in [2022] IEHC 365 (Primeline VNE Ltd v Centz Retail Holdings Ltd), a summary judgment application over unpaid invoices of €140,986. The pattern — a logistics company repeatedly in commercial disputes — suggests a business operating under significant operational and financial strain. Customers named in the current case include Musgrave, GE Medical, and Beko-Whirlpool: household names whose supply chains run through Primeline's warehouses. Watch for the High Court outcome to determine whether Primeline's business model survives intact.
Business Post coverage this week — led by Oisín Gaffey and Donal MacNamee — made clear that while pharmaceuticals are currently exempt from Trump's new 10% global tariff, the Irish Fiscal Advisory Council has warned the US administration may accelerate review findings targeting the sector. Ireland's pharma exports to the US are enormous: companies like Eli Lilly, Novo Nordisk, and Pfizer manufacture in Ireland for the US market. The article quotes PwC's John O'Loughlin noting that Irish exporters may be able to recover duties paid under the now-illegal IEEPA tariffs. The so-what: Ireland's pharmaceutical sector — which accounts for the majority of Irish goods exports — is operating on borrowed time. The exemption is a reprieve, not a resolution. Watch for Section 301 investigations into pharmaceutical pricing, flagged in the article, as the next trigger point.
Knight Frank's Joan Henry told Business Post this week that Irish commercial real estate investment is forecast to rise at least 30% in 2026, from €2.4 billion in 2025. The data reveals a structural shift: industrial and logistics — currently just 10% of investment — is expected to double to 20-25% of the total. This is the Primeline story in reverse: while individual logistics tenants are in court over warehouse disputes, institutional capital is pouring into the asset class. US funds (Greystar, Realty Income) and French capital (Corum) are active buyers. The living sector (build-to-rent, co-living) accounted for 24% of 2025 investment. The week's property register data confirms Dublin residential prices remain elevated: 31 transactions recorded, median €460,000, with a Clontarf house transacting at €1.525 million.
The Radar: Three Signals Worth Watching
Two Companies That Tell the Bigger Story
This week's deep dives focus on two companies: Uniphar, the Irish pharma services group quietly building toward a €200 million EBITDA target while the sector faces tariff threats, and Noel Kelly Management (Holdings) Limited, the talent agency holding company whose CRO filings reveal a carefully constructed corporate architecture behind the headline dividend numbers. Two very different businesses — one a listed pharma distributor, one a private talent agency — but both illustrative of how Irish companies are structuring for growth and resilience.
Uniphar — The Pharma Distributor Betting on Complexity
Uniphar is not a household name, but it is one of the most strategically positioned companies in Irish healthcare. The Dublin-headquartered group operates across three divisions: a pharma division that provides manufacturers and hospitals with access to specialty and unlicensed medicines; a medtech division acting as a European middleman for medical device equipment; and a supply chain and retail division encompassing 482 pharmacies. CEO Ger Rabbette told Business Post this week that the €200 million EBITDA target by 2028 is within reach, driven primarily by the pharma division's high margins and the increasing complexity of specialty healthcare supply chains. CRO records confirm multiple Uniphar entities including Uniphar Pharma Solutions Limited (company 728770, registered November 2022, Citywest Business Campus) and Uniphar BD Limited (company 739502, registered April 2023), both classified under Activities of Holding Companies — a structure consistent with a group managing multiple operating subsidiaries.
| Metric | Current | Target / Prior | Change |
|---|---|---|---|
| EBITDA target | Tracking toward €200m | €200m by 2028 | On track |
| Pharma division revenue growth | High growth, high margin | Primary growth driver | Accelerating |
| Retail pharmacies | 482 units | Foundation of business | Stable |
| New distribution centre | 330,000 sq ft Dublin | Transforms cost base | Operational |
| Medtech division | High margin European middleman | Secondary growth driver | Growing |
The question for 2026 accounts: can Uniphar's pharma division maintain its margin trajectory as the specialty medicines market becomes more competitive, and does the new distribution centre deliver the cost transformation promised?
Noel Kelly Management (Holdings) Limited — The Architecture of a Talent Empire
Registered on 6 June 2019 at Unit B2, Calmount Office Park, Ballymount, Dublin 12 (eircode D12YR44), Noel Kelly Management (Holdings) Limited (CRO number 651334) is the holding vehicle for one of Ireland's most prominent talent agencies. Director Noel Kelly (DOB 24/11/1962) and secretary Catriona Cleary Kelly control a structure that owns 85% of Cleary Consultancy Limited (the NK Management talent agency, representing Pat Kenny, Baz Ashmawy, Ivan Yates, Matt Cooper, Caitríona Perry, and Doireann Garrihy) and 80% of Century Merchandising Services Limited (CMS), a marketing agency. The holding company's issued share capital is just €738 — a nominal figure for a company channelling over €1.5 million annually in dividends.
| Metric | 2025 | 2024 | Change |
|---|---|---|---|
| Total dividends received (Holdings) | €1,500,000 | Not reported | Bumper year |
| NK Management (Cleary Consultancy) dividend | €1,000,000 | — | Paid from €1.25m retained earnings |
| NK Management profits | €92,000 | — | Modest |
| CMS dividend | €550,000 | — | Paid from retained earnings |
| CMS profits | €428,000 | €339,000 | +26% |
| CMS retained earnings post-dividend | €1,200,000 | — | Healthy |
| Director's loan repaid | €372,000 | — | Kelly's capital returned |
The question for 2025 accounts: with NK Management's retained earnings substantially drawn down, will the holding company's dividend income moderate — and does the CMS growth trajectory (profits up 26%) compensate?
Key People This Period
| Name | Role | Notable Activity | Connections |
|---|---|---|---|
| Noel Kelly | Director, NK Management Holdings | €1.5m dividend received; €372k director loan repaid | Cleary Consultancy, Century Merchandising Services |
| John Collison | President, Stripe | $159bn valuation; PayPal acquisition talks; SaaS commentary | Stripe Dublin subsidiary ($5.1bn revenue) |
| Patrick Collison | CEO, Stripe | $1.9trn payments processed; Tempo blockchain incubated | Stripe, EU Inc initiative |
| Ger Rabbette | CEO, Uniphar | €200m EBITDA target by 2028; new 330,000 sq ft distribution centre | Uniphar Pharma Solutions |
| Dave Lewis | CEO, Diageo | Dividend cut 51%; price repositioning; $625m cost reduction programme | Diageo global restructure |
| Lynne Embleton | CEO, Aer Lingus | Navigating Dublin Airport cap ruling and pilot relations | IAG, Irish Air Line Pilots Association |
| Kieran Wallace | Head of Ireland, Interpath | Led 50% revenue growth; parent sold to Bridgepoint for £800m | Interpath Ireland, Bridgepoint PE |
| Charlie Etheridge | CEO, Echelon Data Centres | €1.7bn Morgan Stanley financing secured; Iberdrola JV in Spain | Morgan Stanley, Iberdrola |
One to Watch: Interpath Ireland
Interpath Ireland
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | €19.6m | €13.1m (+50%) |
| Advisory revenue | €7.3m | €2.7m (+170%) |
| Insolvency revenue | €12.3m | €10.3m (+19%) |
| Pre-tax loss | €1.04m | €5.7m (improved) |
| Headcount | 85 | 61 (+39%) |
Interpath Ireland was formed in 2021 when HIG Capital acquired KPMG UK's restructuring business. Led by Kieran Wallace, the Irish operation has built a track record across insolvency mandates including Powerscourt Distillery, Waterford Whisky, CityJet, East Coast Bakehouse, and EuroGiant.
Why it matters: Interpath is a barometer for corporate distress in Ireland. Its 50% revenue growth in 2025 — and the near-tripling of advisory revenue — signals that M&A and restructuring activity is accelerating. The parent firm's £800 million sale to Bridgepoint is a vote of confidence in the Irish and UK restructuring market. This is a company readers would not find without this newsletter — and its trajectory tells you more about the health of the Irish corporate sector than any single headline.
The number that matters: €7.3 million in advisory revenue, up from €2.7 million — a 170% increase in a single year. That is not organic growth; that is a company winning mandates at scale. Watch for Interpath to announce further senior hires and potentially a third office in 2026.
Courts, Property, and the Week Ahead
The Companies Registration Office
The CRO's official records this week confirmed several of the week's key corporate stories. Revolut Ltd (company 909724) and Revolut Bank UAB (company 909790) are both registered at 2 Dublin Landings — the dual-entity structure underpinning Revolut's Irish regulatory footprint. Noel Kelly Management (Holdings) Limited (company 651334, eircode D12YR44) confirms the holding structure behind the week's talent agency dividend story. New company formations continue at pace: 459 companies were registered in the period, with 278 new business names also filed.
| Company | CRO Number | Status | Relevance |
|---|---|---|---|
| Revolut Ltd | 909724 | Normal | Registered Jan 2022, 2 Dublin Landings; payments entity |
| Revolut Bank UAB | 909790 | Normal | Registered May 2022, 2 Dublin Landings; banking entity |
| Noel Kelly Management (Holdings) | 651334 | Normal | Incorporated June 2019; holding company for NK Management and CMS |
| Uniphar Pharma Solutions | 728770 | Normal | Citywest Business Campus; pharma solutions subsidiary |
| Uniphar BD Limited | 739502 | Normal | Registered April 2023; business development holding entity |
The Irish Courts
The High Court delivered six judgments in the period 19–25 February 2026, with the most business-relevant being a personal bankruptcy case and an employment dispute involving Kepak Cork Unlimited Company, one of Ireland's largest meat processors. The Primeline logistics case — reported by Business Post — was heard in the Commercial List but no judgment was delivered in the period; it is proceeding to a full hearing. The judgments index confirms Primeline VNE Limited has prior High Court history, having appeared in [2022] IEHC 365 in a commercial dispute over unpaid invoices.
| Citation | Parties | Subject | Why It Matters |
|---|---|---|---|
| [2026] IEHC 94 | Pisarski v Kepak Cork Unlimited Company | Employment / personal injury | Kepak is one of Ireland's largest meat processors; employment litigation signals HR risk in food sector |
| [2026] IEHC 100 | Re: Phelan [A Bankrupt] | Personal insolvency / bankruptcy | Personal bankruptcy proceedings; indicator of individual financial distress |
| [2026] IEHC 112 | F.A.Y [Nigeria] v Minister For Justice [No. 2] | Immigration / judicial review | Second judicial review in same case; signals ongoing immigration system pressure |
| [2026] IEHC 88 | Child and Family Agency v Guardian Ad Litem | Child welfare / family law | Tusla litigation; family court system under pressure |
Property Markets & Plans
The Irish residential property market recorded 31 transactions in Dublin alone during the week of 19–25 February 2026, with an average price of €529,408 and a median of €460,000. The highest transaction recorded was €1.525 million for a property at 27 Kincora Road, Clontarf, Dublin 3 — a premium coastal address that reflects the sustained demand for quality stock in established Dublin neighbourhoods. Knight Frank's forecast of 30% growth in commercial real estate investment in 2026 — reported by Business Post — is consistent with the institutional activity visible in the property register, where US and European funds continue to acquire Irish assets.
| Address | County | Price | Date |
|---|---|---|---|
| 27 Kincora Rd, Clontarf, Dublin 3 | Dublin | €1,525,000 | 20 Feb 2026 |
| 3 Londonbridge Rd, Sandymount, Dublin 4 | Dublin | €650,000 | 20 Feb 2026 |
| 50 Kiltipper Close, Aylesbury, Tallaght | Dublin | €585,000 | 20 Feb 2026 |
| 9 Brookwood Heights, Artane, Dublin 5 | Dublin | €505,000 | 20 Feb 2026 |
| 16 Cedarwood Avenue, Ballymun, Dublin 11 | Dublin | €460,000 | 20 Feb 2026 |
The Week Ahead
The week of 19–25 February 2026 will be remembered as the week Ireland's dual exposure — to AI-driven tech growth and US trade policy risk — came into sharpest focus. Stripe's $159 billion valuation and Revolut's $100 billion ambition represent the upside of Ireland's position as a hub for global tech and fintech. The pharmaceutical tariff threat represents the downside: a sector that generates the majority of Irish goods exports is operating on a regulatory exemption that could be withdrawn at any time. The Echelon data centre financing deal, meanwhile, signals that the AI infrastructure buildout is accelerating in Ireland regardless of macro headwinds.
What to Watch: (1) The CJEU's final ruling on Dublin Airport's passenger cap — if it upholds the advocate general's opinion, US airlines will escalate pressure on the Irish government. (2) Any US announcement of Section 301 investigations into pharmaceutical pricing — this is the trigger that would put Irish pharma exports directly in the crosshairs. (3) Revolut's H2 2026 share sale process — the valuation it achieves will set a benchmark for European fintech and signal whether the pre-IPO market has recovered from its 2025 volatility.